Relationship of focally amplified long noncoding on chromosome 1 (FAL1) lncRNA with E2F transcription factors in thyroid cancer

Medicine (United States)

Volumn 95, Issue 4, 2016, Pages

  Jeong, Seonhyang ^a   Lee, Jandee ^b   Kim, Daham ^a   Seol, Mi Youn ^b   Lee, Woo Kyung ^a   Jeong, Jong Ju ^b   Nam, Kee Hyun ^b   Jung, Sang Geun ^c   Shin, Dong Yeob ^a   Lee, Eun Jig ^a   Chung, Woong Youn ^b   Jo, Young Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c CHA University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; E2F1 PROTEIN, HUMAN; E2F2 PROTEIN, HUMAN; FOCALLY AMPLIFIED LONG NONCODING RNA ON CHROMOSOME 1, HUMAN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; VASCULOTROPIN A;

ADULT; ARTICLE; CELL CYCLE; CELL CYCLE PROGRESSION; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYCLIN D1 GENE; E2F TRANSCRIPTION FACTORS 1 GENE; E2F TRANSCRIPTION FACTORS 2 GENE; FEMALE; FOCALLY AMPLIFIED LONG NONCODING ON CHROMOSOME 1 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; P21 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; THYROID CARCINOMA; UPREGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; CARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID GLAND; THYROID TUMOR; TUMOR CELL LINE;

ADULT; CARCINOMA; CELL LINE, TUMOR; CROSS-SECTIONAL STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; E2F1 TRANSCRIPTION FACTOR; E2F2 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; RNA, LONG NONCODING; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84957928480     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002592     Document Type: Article

References (51)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
2. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99:E276-E285.
3. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-Term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-1214.
5. Lee J, Jeong S, Park JH, et al. Aberrant expression of COT is related to recurrence of papillary thyroid cancer. Medicine (Baltimore). 2015;94:e548.
6. Lee J, Seol MY, Jeong S, et al. A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma. Medicine (Baltimore). 2015;94:e380.
7. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: A study of 1066 patients. J Clin Endocrinol Metab. 2012;97:1250-1257.
8. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
9. Vasko V, Espinosa AV, Scouten W, et al. Gene expression and functional evidence of epithelial-To-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA. 2007;104:2803-2808.
10. Higgs PG, Lehman N. The RNA world: molecular cooperation at the origins of life. Nat Rev Genet. 2015;16:7-17.
11. Morris KV, Mattick JS. The rise of regulatory RNA. Nat Rev Genet. 2014;15:423-437.
12. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861-874.
13. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223-227.
14. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7-21.
15. He H, Li W, Liyanarachchi S, et al. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab. 2015;100:E164-E172.
16. Jendrzejewski J, He H, Radomska HS, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA. 2012;109:8646-8651.
17. Wang Y, Guo Q, Zhao Y, et al. BRAF-Activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8:1947-1952.
18. Sati S, Ghosh S, Jain V, et al. Genome-wide analysis reveals distinct patterns of epigenetic features in long non-coding RNA loci. Nucleic Acids Res. 2012;40:10018-10031.
19. Hu X, Feng Y, Zhang D, et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014;26:344-357.
20. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65:3980-3985.
21. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11-20.
22. Sato K, Hamada M, Asai K, et al. CENTROIDFOLD: A web server for RNA secondary structure prediction. Nucleic Acids Res. 2009;37:W277-W280.
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102: 15545-15550.
24. Ahn HS, Kim HJ, Welch HG. Koreas thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767.
25. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381discussion 381-384.
26. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328.
27. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630.
28. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493-1501.
29. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32: 2718-2726.
30. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42-50.
31. Shi X, Liu R, Qu S, et al. Association of TERT promoter mutation 1, 295, 228 C < T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2015;100:E632-E637.
32. Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-Analysis. Endocr Relat Cancer. 2015;22:159-168.
33. Lan X, Zhang H, Wang Z, et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene. 2015;569:109-117.
34. Yoon H, He H, Nagy R, et al. Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer. 2007;121:767-775.
35. Tsoi LC, Iyer MK, Stuart PE, et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol. 2015;16:24.
36. el-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995;55:2910-2919.
37. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-Term follow-up. Clin Cancer Res. 1996;2:1591-1599.
38. Barboule N, Mazars P, Baldin V, et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer. 1995;63:611-615.
39. Kim HJ, Sohn SY, Jang HW, et al. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg. 2013;37:376-384.
40. Lee YA, Jung HW, Kim HY, et al. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: A retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab. 2015;100: 1619-1629.
41. Neuman E, Sellers WR, McNeil JA, et al. Structure and partial genomic sequence of the human E2F1 gene. Gene. 1996;173:163-169.
42. Yang R, Muller C, Huynh V, et al. Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Mol Cell Biol. 1999;19:2400-2407.
43. Kong HJ, Yu HJ, Hong S, et al. Interaction and functional cooperation of the cancer-Amplified transcriptional coactivator activating signal cointegrator-2 and E2F-1 in cell proliferation. Mol Cancer Res. 2003;1:948-958.
44. Chafin CB, Regna NL, Caudell DL, et al. MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFkappaB activation in vitro. Cell Mol Immunol. 2014;11:79-83.
45. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667-3670.
46. Knoll M, Lodish HF, Sun L. Long non-coding RNAs as regulators of the endocrine system. Nat Rev Endocrinol. 2015;11:151-160.
47. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-977.
48. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3:520-533.
49. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596-599.
50. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12:433-446.
51. Modarresi F, Faghihi MA, Lopez-Toledano MA, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol. 2012;30:453-459.